iothalamic acid has been researched along with ADPKD in 5 studies
Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 241 ADPKD patients, 15-46 years, with creatinine clearance of 70 ml/min and above had iothalamate clearance, magnetic resonance, and ultrasound evaluations." | 1.42 | A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. ( Bae, KT; Bhutani, H; Chapman, AB; Ge, Y; Gibbs, P; Grantham, JJ; Landslittel, D; Mittal, A; Mrug, M; O'Neill, WC; Rahbari-Oskoui, F; Smith, V; Torres, VE; Wu, Z, 2015) |
| "In these ADPKD patients, copeptin was associated with the various markers of disease severity in ADPKD (positively with total renal volume [R=0." | 1.37 | Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. ( Bakker, SJ; de Jong, PE; Gansevoort, RT; Meijer, E; Navis, G; Struck, J; van der Jagt, EJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhutani, H | 1 |
| Smith, V | 1 |
| Rahbari-Oskoui, F | 1 |
| Mittal, A | 1 |
| Grantham, JJ | 3 |
| Torres, VE | 4 |
| Mrug, M | 2 |
| Bae, KT | 3 |
| Wu, Z | 1 |
| Ge, Y | 1 |
| Landslittel, D | 1 |
| Gibbs, P | 1 |
| O'Neill, WC | 1 |
| Chapman, AB | 3 |
| Meijer, E | 1 |
| Bakker, SJ | 1 |
| van der Jagt, EJ | 1 |
| Navis, G | 1 |
| de Jong, PE | 1 |
| Struck, J | 1 |
| Gansevoort, RT | 1 |
| King, BF | 3 |
| Wetzel, LH | 2 |
| Martin, D | 2 |
| Lockhart, ME | 2 |
| Bennett, WM | 2 |
| Moxey-Mims, M | 2 |
| Abebe, KZ | 1 |
| Lin, Y | 1 |
| Bost, JE | 2 |
| Irazabal, MV | 1 |
| Hogan, MC | 1 |
| Glockner, J | 1 |
| Ofstie, TG | 1 |
| Krasa, HB | 1 |
| Ouyang, J | 1 |
| Czerwiec, FS | 1 |
| Guay-Woodford, L | 1 |
| Landsittel, D | 1 |
| Li, J | 1 |
| Harris, PC | 1 |
| Flessner, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Longitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease Patients (LET-PKD Study)[NCT02729662] | 118 participants (Actual) | Interventional | 2016-10-01 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for iothalamic acid and ADPKD
| Article | Year |
|---|---|
Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Contrast Media; Creatini | 2011 |
4 other studies available for iothalamic acid and ADPKD
| Article | Year |
|---|---|
A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.
Topics: Adolescent; Adult; Area Under Curve; Contrast Media; Creatinine; Female; Follow-Up Studies; Humans; | 2015 |
Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
Topics: Adult; Albuminuria; Biomarkers; Cross-Sectional Studies; Female; Glomerular Filtration Rate; Glycope | 2011 |
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease.
Topics: Adult; Age Factors; Cholesterol, HDL; Disease Progression; Female; Follow-Up Studies; Glomerular Fil | 2011 |
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Topics: Adolescent; Adult; Age of Onset; Disease Progression; Female; Glomerular Filtration Rate; Humans; Io | 2012 |